Plasma tau phosphorylated at threonine 217 (P-tau217) shows promise as a biomarker for Alzheimer disease.
Older adults with both hearing and visual impairments — dual sensory impairment — are at a significantly increased risk for dementia.
At AAIC 2020, 2 presentations separately discussed observing a reduced risk of AD in patients who received the influenza and pneumonia vaccines.
Researchers conducted a randomized clinical trial to assess whether 24 weeks of treatment with rotigotine can modify cognitive functions in patients with mild to moderate Alzheimer disease.
Older adults who have surgery with general anesthesia may experience a modest cortical thinning in the brain, but it does not appear to be tied to Alzheimer disease.
Biogen has submitted its Biologics License Application (BLA) to the Food and Drug Administration (FDA) for aducanumab as a treatment of Alzheimer disease (AD).
Patients with Alzheimer disease have increased iron concentration in the deep gray matter and neocortical regions compared with healthy controls.
Having increased body weight or abdominal obesity is associated with increased incidence of dementia.
The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease (AD) agitation.
Cognitively normal women have increased Alzheimer disease endophenotype, with higher β-amyloid deposition, lower glucose metabolism, and lower gray and white matter volumes.